Drug Discovery · New Haven, CT · Founded 2019 · Publicly Held
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. VeraDermics (NYS: MANE) is based in New Haven, CT and was founded in 2019. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $596 million (Feb 2026). It has raised $519 million across 1 recorded round; the latest was a $150 million Series C in Oct 2025.
Last price · $/share
—
Implied valuation
$596.3M
Total raised
$518.6M
Last round
Later Stage VC (Series C)
Oct 2025
Cap table — not yet on record
VeraDermics (NYS: MANE)'s share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Where does VeraDermics (NYS: MANE)'s cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across VeraDermics (NYS: MANE)'s 1 recorded funding rounds.
